Uncategorized
VIVID, VISTA: BCVA better with aflibercept than laser for treatment of DME
ORLANDO, Fla. — Intravitreal aflibercept for diabetic macular edema continues to perform better than laser with regard to best corrected visual acuity, according to a presenter giving 2-year subgroup analysis data of the VIVID and VISTA DME studies here at the Association for Research in Vision and Ophthalmology meeting. Four hundred six patients in the VIVID study and 466 patients in the VISTA study were divided into three arms: those who underwent laser photocoagulation plus sham injection, those who received five monthly intravitreal injections of 2 mg Eylea(aflibercept, Regeneron) followed (Read more...)